APGE

Apogee Therapeutics, Inc. - Common Stock (APGE) | Rumor.io

Apogee Therapeutics

APGE

Attention (50-day avg)0%

Attention rank (50-day avg)#2,244

Bullish sentiment (50-day avg)38%

Price to earnings ratio-36.1

Market capitalization10.2B

Earnings per share-4.34

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-255.8M

Social

What share of all stock conversation is about APGE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Jun 24

Apogee Therapeutics, Inc. (APGE) has been acquired by AbbVie for $10.9B in a cash deal at $135.11 per share.
The acquisition is primarily for Apogee's drug zumilokibart, which AbbVie could market as a potential rival to its existing immunology treatments.
The deal has been approved by both boards, with closing expected in Q3, and has been cut to neutral from buy by Guggenheim and outperform by Mizuho.

Generated by AI

Sentiment

Of the messages about APGE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +68.52	67.8% -17.61
Bearish	—	—	0% -68.52	32.2% +17.61

Bullish· Jun 22

Apogee Therapeutics ($APGE) has been acquired by AbbVie ($ABBV) for $135.11 per share in cash, valuing the company at approximately $11 billion.
The acquisition is seen as a strategic move by AbbVie to strengthen its pipeline and address its patent cliff, particularly with Apogee's phase 2 eczema treatment and asthma combo therapy.
The deal is expected to drive growth in AbbVie's immunology business, with the acquisition being seen as a positive step towards achieving its next-generation growth push.

Bearish· Jul 7

$APGE's price action has been severely weak, with a sharp decline from its market high of $70.
The company's AE profile has set a high bar for safety and efficacy, leading to a "sell the news" reaction and a significant loss in value.
$APGE's sales projections, particularly for APG777, are unlikely to be met, with some doubting it will even reach $1.5B.

Generated by AI

Topics

Of the messages about APGE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	87.26%
Analysts	—	0%	0%	5.43%
Technical Analysis	—	0%	0%	4.35%
Controversies	—	0%	0%	0.74%
Earnings	—	0%	0%	0.07%
Macro	—	0%	0%	2.15%

Announcements· Jun 22

AbbVie is acquiring Apogee Therapeutics in a cash deal valued at approximately $11 billion, representing a 60% premium over Apogee's recent closing price.
The acquisition adds a diverse pipeline of assets focused on inflammatory and immunological diseases, including atopic dermatitis, asthma, and other related conditions.
The deal is expected to strengthen AbbVie's drug development pipeline, particularly in immunology, and is set to close in the third quarter of 2026.

Technical Analysis· Mar 23

Apogee Therapeutics, Inc. ($APGE) is coiling within a symmetrical triangle, awaiting resolution.
A decisive breakout above $71.62 resistance on high volume ($2.2M) has been confirmed, targeting a potential move of $104.32 (+22.14%).
Positive Phase 2 data for atopic dermatitis candidate APG777 has been reported, showing maintained response with quarterly and semi-annual dosing.

Generated by AI

Community

Of the messages about APGE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	78.57%	67.12%	66.03%
Newcomers	100%	21.43%	32.88%	33.97%

Regulars· Jun 22

AbbVie is acquiring Apogee Therapeutics, Inc. for approximately $10.9 billion, with Apogee shareholders to receive $135.11 per share in cash.
The acquisition is a strategic move to deepen AbbVie's immunology portfolio and add a diverse pipeline of assets, including a phase 2 atopic dermatitis candidate and an asthma combo therapy.
The deal is expected to boost AbbVie's pipeline and potentially elevate the standard of care for patients with dermatologic, respiratory, and other related inflammatory and immunological diseases.

Newcomers· Jun 23

The acquisition of Apogee Therapeutics ($APGE) by AbbVie ($ABBV) for $10.9 billion in cash is a significant deal, with $APGE stock price increasing by 47% to $135.11 per share.
The deal's success hinges on deal approval, timing, and the closing spread, with the key variable being the drug zumilokibart, a late-stage IL-13 antibody with quarterly or twice-yearly maintenance dosing.
The acquisition is a testament to the US healthcare market's trend of high prices for new drugs, even when they offer only marginal improvements over existing treatments, raising questions about AbbVie's potential success in selling the drug globally.

Generated by AI

On September 3, AbbVie Inc. (NYSE:ABBV) finalized its acquisition of clinical-stage biotech Apogee Therapeutics, Inc. (NASDAQ:APGE) for $135.11 per share in cash. The $10.9 billion buyouts immediately fold Apogee’s promising inflammatory and immunology (I&I) pipeline into AbbVie’s commercial engine. On the exact same day, AbbVie separately reported positive Phase 3 Cervino trial results for its […]

20d agofinance.yahoo.com

Apogee Therapeutics Completes Merger and Plans Nasdaq Delisting

Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.

25d agoThe Globe and Mail

AbbVie seals $11B acquisition of Apogee Therapeutics (ABBV:NYSE)

26d agoSeeking Alpha

AbbVie Completes Acquisition of Apogee Therapeutics

AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Apogee Therapeutics, Inc. (NASDAQ: APGE). With completion of the acquisition, Apogee is now part of AbbVie. Under the terms of the agreement, Apogee shareholders received $135.11 per share in cash, for a total equity value of approximately $10.9 billion.

26d agoYahoo Finance

AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics

AbbVie (ABBV) said Thursday that it has completed its acquisition of Apogee Therapeutics (APGE), val

27d agoYahoo Finance

Apogee Therapeutics stock hits all-time high at 134.89 USD

1mo agoInvesting.com

Also Discussed

Investors talking about APGE also mention

#	Name	Attention
1	Spyre Therapeutics, Inc.SYRE	0%new
2	Regenxbio Inc.RGNX	0%+0
3	Abivax SAABVX	0.01%-0.01
4	Nektar TherapeuticsNKTR	0.08%+0.03
5	Invesco Top QQQ ETFQBIG	0%0
6	Janux Therapeutics, Inc.JANX	0%0
7	Revolution Medicines, Inc.RVMD	0.01%-0.01
8	Kymera Therapeutics Inc.KYMR	0%0
9	Edgewise Therapeutics Inc.EWTX	0%new
10	Celcuity Inc.CELC	0%0

Apogee Therapeutics, Inc. - Common Stock

Healthcare
Biotechnology

Apogee Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel biologic therapies for inflammatory and immunology conditions. Its programs target diseases such as atopic dermatitis, asthma, eosinophilic esophagitis, and chronic obstructive pulmonary disease, areas where current treatment options can leave important unmet needs. The company centers its research on antibody-based medicines designed to improve durability, dosing convenience, and therapeutic performance through advanced engineering. Apogee Therapeutics Inc. also explores combination and monotherapy approaches across dermatology, respiratory, and gastroenterology-related indications. Headquartered in Waltham, Massachusetts and founded in 2022, the company plays a role in the biopharmaceutical market by advancing specialized treatments for patients with chronic immune-mediated disorders.

Website

Location

One Letterman Drive

San Francisco, CA, 94129-1492

United States

Social

What share of all stock conversation is about APGE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Jun 24

Apogee Therapeutics, Inc. (APGE) has been acquired by AbbVie for $10.9B in a cash deal at $135.11 per share.
The acquisition is primarily for Apogee's drug zumilokibart, which AbbVie could market as a potential rival to its existing immunology treatments.
The deal has been approved by both boards, with closing expected in Q3, and has been cut to neutral from buy by Guggenheim and outperform by Mizuho.

Generated by AI

Sentiment

Of the messages about APGE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +68.52	67.8% -17.61
Bearish	—	—	0% -68.52	32.2% +17.61

Bullish· Jun 22

Apogee Therapeutics ($APGE) has been acquired by AbbVie ($ABBV) for $135.11 per share in cash, valuing the company at approximately $11 billion.
The acquisition is seen as a strategic move by AbbVie to strengthen its pipeline and address its patent cliff, particularly with Apogee's phase 2 eczema treatment and asthma combo therapy.
The deal is expected to drive growth in AbbVie's immunology business, with the acquisition being seen as a positive step towards achieving its next-generation growth push.

Bearish· Jul 7

$APGE's price action has been severely weak, with a sharp decline from its market high of $70.
The company's AE profile has set a high bar for safety and efficacy, leading to a "sell the news" reaction and a significant loss in value.
$APGE's sales projections, particularly for APG777, are unlikely to be met, with some doubting it will even reach $1.5B.

Generated by AI

Topics

Of the messages about APGE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	87.26%
Analysts	—	0%	0%	5.43%
Technical Analysis	—	0%	0%	4.35%
Controversies	—	0%	0%	0.74%
Earnings	—	0%	0%	0.07%
Macro	—	0%	0%	2.15%

Announcements· Jun 22

AbbVie is acquiring Apogee Therapeutics in a cash deal valued at approximately $11 billion, representing a 60% premium over Apogee's recent closing price.
The acquisition adds a diverse pipeline of assets focused on inflammatory and immunological diseases, including atopic dermatitis, asthma, and other related conditions.
The deal is expected to strengthen AbbVie's drug development pipeline, particularly in immunology, and is set to close in the third quarter of 2026.

Technical Analysis· Mar 23

Apogee Therapeutics, Inc. ($APGE) is coiling within a symmetrical triangle, awaiting resolution.
A decisive breakout above $71.62 resistance on high volume ($2.2M) has been confirmed, targeting a potential move of $104.32 (+22.14%).
Positive Phase 2 data for atopic dermatitis candidate APG777 has been reported, showing maintained response with quarterly and semi-annual dosing.

Generated by AI

Community

Of the messages about APGE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	78.57%	67.12%	66.03%
Newcomers	100%	21.43%	32.88%	33.97%

Regulars· Jun 22

AbbVie is acquiring Apogee Therapeutics, Inc. for approximately $10.9 billion, with Apogee shareholders to receive $135.11 per share in cash.
The acquisition is a strategic move to deepen AbbVie's immunology portfolio and add a diverse pipeline of assets, including a phase 2 atopic dermatitis candidate and an asthma combo therapy.
The deal is expected to boost AbbVie's pipeline and potentially elevate the standard of care for patients with dermatologic, respiratory, and other related inflammatory and immunological diseases.

Newcomers· Jun 23

The acquisition of Apogee Therapeutics ($APGE) by AbbVie ($ABBV) for $10.9 billion in cash is a significant deal, with $APGE stock price increasing by 47% to $135.11 per share.
The deal's success hinges on deal approval, timing, and the closing spread, with the key variable being the drug zumilokibart, a late-stage IL-13 antibody with quarterly or twice-yearly maintenance dosing.
The acquisition is a testament to the US healthcare market's trend of high prices for new drugs, even when they offer only marginal improvements over existing treatments, raising questions about AbbVie's potential success in selling the drug globally.

Generated by AI

Apogee Therapeutics

Social

Jun 24

Bullish· Jun 22

Bearish· Jul 7

Announcements· Jun 22

Technical Analysis· Mar 23

Regulars· Jun 22

Newcomers· Jun 23

Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth?

Apogee Therapeutics Completes Merger and Plans Nasdaq Delisting

AbbVie seals $11B acquisition of Apogee Therapeutics (ABBV:NYSE)

AbbVie Completes Acquisition of Apogee Therapeutics

AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics

Apogee Therapeutics stock hits all-time high at 134.89 USD

Also Discussed

Apogee Therapeutics, Inc. - Common Stock

Company Information

Location

Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth?

Apogee Therapeutics Completes Merger and Plans Nasdaq Delisting

AbbVie seals $11B acquisition of Apogee Therapeutics (ABBV:NYSE)

AbbVie Completes Acquisition of Apogee Therapeutics

AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics

Apogee Therapeutics stock hits all-time high at 134.89 USD

Also Discussed

Social

Jun 24

Bullish· Jun 22

Bearish· Jul 7

Announcements· Jun 22

Technical Analysis· Mar 23

Regulars· Jun 22

Newcomers· Jun 23